Allergy to protamine.
Review published in Clinical reviews in allergy (1991)
Abstract
Recent advances in medicine, such as cardiac catheterization, phoresis, dialysis, and cardiopulmonary bypass technology, have increased the need for heparin anticoagulation. To antagonize heparin's effect and prevent hemorrhagic complications after the procedure, protamine has likewise been used more frequently. With its increased use have come increased reports of adverse protamine reactions consisting of rash, urticaria, elevation of pulmonary artery pressure, systemic hypotension, and, at times, death. The elevation of pulmonary artery pressure, which appears to be a rather common occurrence in animals, may be an isolated finding without clinical consequences in humans. However, this pulmonary vasoconstriction may, when severe, lead to acute right-sided heart failure and systemic hypotension. Other protamine reactions involve a decrease in systemic vascular resistance and systemic hypotension without changes in pulmonary artery pressure. Causes of acute protamine reactions may involve the generation of anaphyatoxins and prostanoids either from protamine-heparin complexes or complement-fixing antiprotamine IgG antibodies, from inhibition of plasma Carboxypeptidase N, from crosslinking of cell-surface antiprotamine IgE on mast cells and basophils with subsequent mediator release, or from potentiation of IgE-mediated release of histamine through a polycationin-recognition site. Although we have come a long way in understanding the mechanisms by which protamine can cause its ill effects in humans, more work is clearly needed to define, in prospective studies, the incidence of and risk factors for protamine reactions in various patient groups, and to delineate more clearly which mechanisms are involved in each clinical type of acute protamine reaction. Hopefully, this will lead to strategies and protamine alternatives that will prevent or diminish, in frequency or severity, adverse protamine reactions. Alternatively, a clearer picture of the risk factors important for protamine reactions and the predictive value of diagnostic tests (e.g., protamine IgE antibody) can also minimize the clinical impact of this increasingly common adverse event.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Recent advances in medicine, such as cardiac catheterization, phoresis, dialysis, and cardiopulmonary bypass technology, have increased the need for heparin anticoagulation. To antagonize heparin's effect and prevent hemorrhagic complications after the procedure, protamine has likewise been used more frequently.
Por qué esto importa para la hirudoterapia
Esta revisión examinó las reacciones adversas a la protamina, el fármaco utilizado habitualmente para revertir la anticoagulación con heparina tras procedimientos como el cateterismo cardíaco, la diálisis y la circulación extracorpórea. La revisión describe múltiples mecanismos de las reacciones a la protamina —incluidos anticuerpos IgG antiprotamina fijadores de complemento, liberación de mediadores por mastocitos y basófilos mediada por IgE, generación de anafilotoxinas y vasoconstricción pulmonar— y señala la necesidad de estudios prospectivos para definir la incidencia, los factores de riesgo y las alternativas a la protamina. Esto es indirectamente relevante para el ámbito de ASH porque la necesidad clínica de alternativas a la protamina se cruza con el interés en los inhibidores directos de la trombina de la clase de la hirudina, que no requieren reversión con protamina y, por tanto, podrían soslayar estos riesgos de reacciones adversas. Advertencia: la revisión no aborda sanguijuelas, hirudoterapia ni hirudina; su relevancia para el ámbito de ASH es indirecta, basada únicamente en el contexto clínico más amplio de los retos del manejo de la anticoagulación.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026